Translation of Anticancer Efficacy From Nonclinical Models to the Clinic

Mouse cancer models have provided critical insights into tumor biology; however, clinical translation of these findings has been challenging. This perspective posits that factors impacting on successful translation start with limitations in capturing human cancer pathophysiology and end with challen...

Full description

Saved in:
Bibliographic Details
Published in:CPT: pharmacometrics and systems pharmacology 2014-08, Vol.3 (8), p.1-4
Main Authors: Stroh, M, Duda, DG, Takimoto, CH, Yamazaki, S, Vicini, P
Format: Article
Language:English
Subjects:
Biomarkers
Cancer therapies
Decision making
Drug development
Drug dosages
Extracellular matrix
FDA approval
Oncology
Regulatory approval
Stockholders
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4538-53b85c2a1f22e3725cfc61b5fe0c15f379c620bc2097f4c949ba4d61cfc1915d3
cites cdi_FETCH-LOGICAL-c4538-53b85c2a1f22e3725cfc61b5fe0c15f379c620bc2097f4c949ba4d61cfc1915d3
container_end_page 4
container_issue 8
container_start_page 1
container_title CPT: pharmacometrics and systems pharmacology
container_volume 3
creator Stroh, M
Duda, DG
Takimoto, CH
Yamazaki, S
Vicini, P
description Mouse cancer models have provided critical insights into tumor biology; however, clinical translation of these findings has been challenging. This perspective posits that factors impacting on successful translation start with limitations in capturing human cancer pathophysiology and end with challenges in generating robust translatable preclinical end points. A comprehensive approach that considers clinically relevant mouse models with both an integrated biomarker strategy and a complementary modeling and simulation effort will strengthen the current oncology drug development paradigm. CPT Pharmacometrics Syst. Pharmacol. (2014) 3, e128; doi:10.1038/psp.2014.28; published online 06 August 2014
doi_str_mv 10.1038/psp.2014.28
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4150926</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2289672862</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4538-53b85c2a1f22e3725cfc61b5fe0c15f379c620bc2097f4c949ba4d61cfc1915d3</originalsourceid><addsrcrecordid>eNp9kM1PAjEQxRujEYKcvJsmHg3Yj-1u92JCCIgJKol4brqllSVLu7aLhv_eImjwYi99mfnlzcwD4BKjPkaU39ah7hOEkz7hJ6BNcEp7nKL09Ei3QDeEFYovSxDO0TloEYZyzihqg8ncSxsq2ZTOQmfgwDalklZpD0fGRKm2cOzdGj45q6rSxkoFH91CVwE2DjZLDYff5QtwZmQVdPfwd8DreDQfTnrT5_uH4WDaUwmjvMdowZkiEhtCNM0IU0aluGBGI4WZoVmuUoIKRVCemUTlSV7IZJHiiOEcswXtgLu9b70p1nqhtG28rETty7X0W-FkKf52bLkUb-5DJDgeTdJocH0w8O59o0MjVm7jbdxZEMLzNCM8JZG62VPKuxC8Nr8TMBK75EVMXuySF4RH-up4qV_2J-cI0D3wWVZ6-5-XmL3Mkp2Otl_x3o6U</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2289672862</pqid></control><display><type>article</type><title>Translation of Anticancer Efficacy From Nonclinical Models to the Clinic</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Stroh, M ; Duda, DG ; Takimoto, CH ; Yamazaki, S ; Vicini, P</creator><creatorcontrib>Stroh, M ; Duda, DG ; Takimoto, CH ; Yamazaki, S ; Vicini, P</creatorcontrib><description>Mouse cancer models have provided critical insights into tumor biology; however, clinical translation of these findings has been challenging. This perspective posits that factors impacting on successful translation start with limitations in capturing human cancer pathophysiology and end with challenges in generating robust translatable preclinical end points. A comprehensive approach that considers clinically relevant mouse models with both an integrated biomarker strategy and a complementary modeling and simulation effort will strengthen the current oncology drug development paradigm. CPT Pharmacometrics Syst. Pharmacol. (2014) 3, e128; doi:10.1038/psp.2014.28; published online 06 August 2014</description><identifier>ISSN: 2163-8306</identifier><identifier>EISSN: 2163-8306</identifier><identifier>DOI: 10.1038/psp.2014.28</identifier><identifier>PMID: 25098530</identifier><language>eng</language><publisher>United States: John Wiley &amp; Sons, Inc</publisher><subject>Biomarkers ; Cancer therapies ; Decision making ; Drug development ; Drug dosages ; Extracellular matrix ; FDA approval ; Oncology ; Regulatory approval ; Stockholders</subject><ispartof>CPT: pharmacometrics and systems pharmacology, 2014-08, Vol.3 (8), p.1-4</ispartof><rights>2014 The Authors. CPT: Pharmacometrics &amp; Systems Pharmacology published by Wiley Periodicals, Inc.</rights><rights>2014. This work is published under http://creativecommons.org/licenses/by-nc-nd/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2014 American Society for Clinical Pharmacology and Therapeutics 2014 American Society for Clinical Pharmacology and Therapeutics</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4538-53b85c2a1f22e3725cfc61b5fe0c15f379c620bc2097f4c949ba4d61cfc1915d3</citedby><cites>FETCH-LOGICAL-c4538-53b85c2a1f22e3725cfc61b5fe0c15f379c620bc2097f4c949ba4d61cfc1915d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2289672862/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2289672862?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,44590,46052,46476,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25098530$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stroh, M</creatorcontrib><creatorcontrib>Duda, DG</creatorcontrib><creatorcontrib>Takimoto, CH</creatorcontrib><creatorcontrib>Yamazaki, S</creatorcontrib><creatorcontrib>Vicini, P</creatorcontrib><title>Translation of Anticancer Efficacy From Nonclinical Models to the Clinic</title><title>CPT: pharmacometrics and systems pharmacology</title><addtitle>CPT Pharmacometrics Syst Pharmacol</addtitle><description>Mouse cancer models have provided critical insights into tumor biology; however, clinical translation of these findings has been challenging. This perspective posits that factors impacting on successful translation start with limitations in capturing human cancer pathophysiology and end with challenges in generating robust translatable preclinical end points. A comprehensive approach that considers clinically relevant mouse models with both an integrated biomarker strategy and a complementary modeling and simulation effort will strengthen the current oncology drug development paradigm. CPT Pharmacometrics Syst. Pharmacol. (2014) 3, e128; doi:10.1038/psp.2014.28; published online 06 August 2014</description><subject>Biomarkers</subject><subject>Cancer therapies</subject><subject>Decision making</subject><subject>Drug development</subject><subject>Drug dosages</subject><subject>Extracellular matrix</subject><subject>FDA approval</subject><subject>Oncology</subject><subject>Regulatory approval</subject><subject>Stockholders</subject><issn>2163-8306</issn><issn>2163-8306</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><recordid>eNp9kM1PAjEQxRujEYKcvJsmHg3Yj-1u92JCCIgJKol4brqllSVLu7aLhv_eImjwYi99mfnlzcwD4BKjPkaU39ah7hOEkz7hJ6BNcEp7nKL09Ei3QDeEFYovSxDO0TloEYZyzihqg8ncSxsq2ZTOQmfgwDalklZpD0fGRKm2cOzdGj45q6rSxkoFH91CVwE2DjZLDYff5QtwZmQVdPfwd8DreDQfTnrT5_uH4WDaUwmjvMdowZkiEhtCNM0IU0aluGBGI4WZoVmuUoIKRVCemUTlSV7IZJHiiOEcswXtgLu9b70p1nqhtG28rETty7X0W-FkKf52bLkUb-5DJDgeTdJocH0w8O59o0MjVm7jbdxZEMLzNCM8JZG62VPKuxC8Nr8TMBK75EVMXuySF4RH-up4qV_2J-cI0D3wWVZ6-5-XmL3Mkp2Otl_x3o6U</recordid><startdate>201408</startdate><enddate>201408</enddate><creator>Stroh, M</creator><creator>Duda, DG</creator><creator>Takimoto, CH</creator><creator>Yamazaki, S</creator><creator>Vicini, P</creator><general>John Wiley &amp; Sons, Inc</general><general>Nature Publishing Group</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>201408</creationdate><title>Translation of Anticancer Efficacy From Nonclinical Models to the Clinic</title><author>Stroh, M ; Duda, DG ; Takimoto, CH ; Yamazaki, S ; Vicini, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4538-53b85c2a1f22e3725cfc61b5fe0c15f379c620bc2097f4c949ba4d61cfc1915d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Biomarkers</topic><topic>Cancer therapies</topic><topic>Decision making</topic><topic>Drug development</topic><topic>Drug dosages</topic><topic>Extracellular matrix</topic><topic>FDA approval</topic><topic>Oncology</topic><topic>Regulatory approval</topic><topic>Stockholders</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stroh, M</creatorcontrib><creatorcontrib>Duda, DG</creatorcontrib><creatorcontrib>Takimoto, CH</creatorcontrib><creatorcontrib>Yamazaki, S</creatorcontrib><creatorcontrib>Vicini, P</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Free Archive</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medicine (ProQuest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>CPT: pharmacometrics and systems pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stroh, M</au><au>Duda, DG</au><au>Takimoto, CH</au><au>Yamazaki, S</au><au>Vicini, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Translation of Anticancer Efficacy From Nonclinical Models to the Clinic</atitle><jtitle>CPT: pharmacometrics and systems pharmacology</jtitle><addtitle>CPT Pharmacometrics Syst Pharmacol</addtitle><date>2014-08</date><risdate>2014</risdate><volume>3</volume><issue>8</issue><spage>1</spage><epage>4</epage><pages>1-4</pages><issn>2163-8306</issn><eissn>2163-8306</eissn><abstract>Mouse cancer models have provided critical insights into tumor biology; however, clinical translation of these findings has been challenging. This perspective posits that factors impacting on successful translation start with limitations in capturing human cancer pathophysiology and end with challenges in generating robust translatable preclinical end points. A comprehensive approach that considers clinically relevant mouse models with both an integrated biomarker strategy and a complementary modeling and simulation effort will strengthen the current oncology drug development paradigm. CPT Pharmacometrics Syst. Pharmacol. (2014) 3, e128; doi:10.1038/psp.2014.28; published online 06 August 2014</abstract><cop>United States</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>25098530</pmid><doi>10.1038/psp.2014.28</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2163-8306
ispartof CPT: pharmacometrics and systems pharmacology, 2014-08, Vol.3 (8), p.1-4
issn 2163-8306
2163-8306
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4150926
source Wiley Online Library Open Access; Publicly Available Content Database; PubMed Central
subjects Biomarkers
Cancer therapies
Decision making
Drug development
Drug dosages
Extracellular matrix
FDA approval
Oncology
Regulatory approval
Stockholders
title Translation of Anticancer Efficacy From Nonclinical Models to the Clinic
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A02%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Translation%20of%20Anticancer%20Efficacy%20From%20Nonclinical%20Models%20to%20the%20Clinic&rft.jtitle=CPT:%20pharmacometrics%20and%20systems%20pharmacology&rft.au=Stroh,%20M&rft.date=2014-08&rft.volume=3&rft.issue=8&rft.spage=1&rft.epage=4&rft.pages=1-4&rft.issn=2163-8306&rft.eissn=2163-8306&rft_id=info:doi/10.1038/psp.2014.28&rft_dat=%3Cproquest_pubme%3E2289672862%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4538-53b85c2a1f22e3725cfc61b5fe0c15f379c620bc2097f4c949ba4d61cfc1915d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2289672862&rft_id=info:pmid/25098530&rfr_iscdi=true